Drug Discovery - Research & Development

Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis

Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and extra-terminal motif (BET) small molecule inhibitor, to treat myelofibrosis.

BMS and Microsoft partner for AI-based lung cancer detection

Bristol Myers Squibb (BMS) has entered an agreement with Microsoft to advance AI-driven early lung cancer detection.

Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies

Novo Nordisk and Aspect Biosystems have commenced a new phase in their ongoing partnership focused on curative cellular medicines to treat diabetes.

AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy

AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease

Novartis has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ianalumab, a treatment for Sjögren’s disease, the second most prevalent rheumatic autoimmune condition.

InterAx and Alveus collaborate on small-molecule metabolic treatment

InterAx Biotech has entered a strategic research collaboration and licensing agreement with Alveus Therapeutics to develop a differentiated small-molecule therapeutic candidate for metabolic disease.

Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and potential commercialisation of its botensilimab and balstilimab (BOT/BAL) immunotherapy combination programme.

SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody

SciNeuro Pharmaceuticals has announced a global licensing and collaboration agreement with Novartis to develop SciNeuro’s newly identified de novo amyloid beta antibody programme aimed at treating Alzheimer’s disease.

Atara receives FDA complete response letter for Ebvallo BLA application

Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the biologics licence application (BLA) of Ebvallo (tabelecleucel).